Memantine improved cognition in lupus-associated neuropsychological dysfunction in trial

A phase 2 randomised placebo-controlled trial (ClearMEMory) evaluated memantine, titrated to 40 mg/day over 12 weeks, in adults with SLE and objective neuropsychological dysfunction. The trial reported greater improvement in RBANS total score with memantine (median +8) than placebo (median +5, P=.032), and more memantine-treated participants achieved a clinically important score increase of at least 8 points (66.7% vs 36.0%, P=.047, number-needed-to-treat 3.3); patient-reported global impression of change did not differ significantly between groups, and rates of discontinuation due to adverse events were similar in both arms.

Most relevant for: Adults with systemic lupus erythematosus who have objective neuropsychological or cognitive dysfunction.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.